Related Experiment Video
Updated: Jul 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunotherapy for prostate cancer
1University of California, San Francisco, San Francisco, CA 94143-0511, USA. Lawrence.fong@ucsf.edu
Abstract:
Whereas androgen deprivation and chemotherapy have become the cornerstone of therapy for advanced prostate cancer, novel therapies are being developed that may expand upon currently available treatments. The identification of antigens expressed by prostate tissue and/or prostate cancer that are recognized by T cells or antibodies creates opportunities to develop novel immunotherapeutic approaches including tumor vaccines. Proteins expressed in prostate cancer-including prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen-have been used as immunologic targets for immunotherapy. Moreover, innovations in cancer genomics and proteomics also will aid in the identification of immunologic targets. Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings.
Insights
Novel immunotherapies targeting prostate cancer antigens show promise. These approaches, including tumor vaccines, are expanding treatment options beyond traditional androgen deprivation and chemotherapy, generating both immune and clinical responses in patients.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Advanced prostate cancer treatment relies on androgen deprivation and chemotherapy.
- Immunotherapy offers a novel therapeutic avenue by targeting prostate cancer antigens.
- Key immunologic targets include prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen.
Purpose of the Study:
- To explore novel immunotherapeutic approaches for advanced prostate cancer.
- To highlight the role of identified prostate cancer antigens as targets for immunotherapy.
- To discuss the potential of immunotherapy to improve clinical outcomes.
Main Methods:
- Identification of antigens expressed by prostate tissue and prostate cancer.
- Development of immunotherapeutic strategies, including tumor vaccines.
- Analysis of emerging clinical trial data on immunotherapy efficacy.
Main Results:
- Immunotherapy can elicit significant immune responses in patients.
- Emerging trials indicate that immunotherapy can also lead to clinical responses.
- Innovations in cancer genomics and proteomics are aiding target identification.
Conclusions:
- Immunotherapy represents a promising expansion of advanced prostate cancer treatment options.
- Targeting specific prostate cancer antigens can generate effective immune and clinical responses.
- Future research will focus on optimizing and capitalizing on these immunotherapy findings.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

